): Basic research has led to major breakthroughs in understanding the basic biology of a number of cancers as well as contributed substantially to advances in identifying novel therapeutic strategies specifically targeting tumor cells. The biggest challenge to improving the outcome of patients with cancer lies in the ability to translate these scientific breakthroughs into clinically testable hypothesis and the design of clinical trials with defined and achievable endpoints. A key requisite in the translation of laboratory discoveries into clinical concepts is the availability of clinical investigators who are trained and fluent in both the basic sciences and clinical research. The goal of the UAB Clinical Oncology Research Career Development Program is to stimulate the recruitment and training of young oncologists in basic science and clinical research. The ultimate aim is to develop clinical investigators who are able to """"""""bridge the gap"""""""" between basic science and clinical research and are active in the area of translational investigation. Candidates will be recruited from all oncology specialties within the UAB Cancer Center and other academic institutions. Candidates will be assigned to a basic science area of their choice and receive """"""""hands on"""""""" and didactic training in basic research (Phase I), followed by training in clinical investigation (Phase II) and transition to independent careers in patient-oriented clinical research (Phase III). The program will be a joint effort of basic scientists and clinical investigators within the Cancer Center and candidates will be trained by a faculty of experienced and nationally known investigators. Over the past four years, of the nine fellows that have entered the clinical investigator training program at UAB, six have gone on to undertake academic careers in three different oncologic specialties. These candidates have competed successfully for external funding and have developed or are in the process of developing an independent career in clinical investigation. The proposed program builds on this success and has been enhanced to strengthen the clinical investigation and translational research components.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
1K12CA076937-01
Application #
2541318
Study Section
Special Emphasis Panel (ZCA1-GRB-J (01))
Project Start
1997-09-30
Project End
2002-06-30
Budget Start
1997-09-30
Budget End
1998-06-30
Support Year
1
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Forero, Andres; Meredith, Ruby F; Khazaeli, M B et al. (2005) Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration. Cancer Biother Radiopharm 20:467-78
Forero-Torres, Andres; Shen, Sui; Breitz, Hazel et al. (2005) Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein. Cancer Biother Radiopharm 20:379-90
Luo, Yuhong; Lin, Fang-Tsyr; Lin, Weei-Chin (2004) ATM-mediated stabilization of hMutL DNA mismatch repair proteins augments p53 activation during DNA damage. Mol Cell Biol 24:6430-44
Forero, Andres; Weiden, Paul L; Vose, Julie M et al. (2004) Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Blood 104:227-36
Liu, Kang; Luo, Yuhong; Lin, Fang-Tsyr et al. (2004) TopBP1 recruits Brg1/Brm to repress E2F1-induced apoptosis, a novel pRb-independent and E2F1-specific control for cell survival. Genes Dev 18:673-86
Liu, Kang; Lin, Fang-Tsyr; Ruppert, J Michael et al. (2003) Regulation of E2F1 by BRCT domain-containing protein TopBP1. Mol Cell Biol 23:3287-304
Forero, Andres; Meredith, Ruby F; Khazaeli, M B et al. (2003) A novel monoclonal antibody design for radioimmunotherapy. Cancer Biother Radiopharm 18:751-9